Alembic PharmaQ1 FY26

Alembic Pharma Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,050.65P/E: 23.0Market Cap: ₹20.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

No

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • US business expected to grow 10%-15% for the full year, supported by volume gains and product launches (4 launched in Q1, 10-15 planned for rest of the year).
  • Rest of World (RoW) generics saw 21% growth in Q1; expected to grow 10%-15% for the full year.
  • India business aims to return to double-digit growth within months; currently working on improving execution and aligning with market norms.
  • New manufacturing facilities ramp-up and cost optimization initiatives expected to improve operating leverage and margins.
  • API business has been muted but showing potential for recovery after pricing pressures stabilize.
  • Overall 10% year-on-year revenue growth achieved in Q1, with broad-based growth despite pricing pressures.

See what Alembic Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No specific mention of any new fundraising through debt or equity during the call.
  • Gross debt as of June 30, 2025, stands at Rs. 1,185 crores and net debt at Rs. 967 crores, broadly similar to March levels.
  • Future debt movement is expected to depend on working capital needs and business growth trajectory.
  • Management is cautious and will reassess debt reduction or increases in upcoming quarters based on US market dynamics.
  • No indication of equity fundraising discussed in the call.

See what Alembic Pharma management said on order book — free account, 30 seconds.

Capex plans

No
  • Most new capacity augmentation projects have been completed.
  • Current CAPEX is primarily directed towards maintenance, replacement, and debottlenecking wherever necessary.
  • There is very little CAPEX planned for major expansion or upgrades at this time.
  • The company guided for a CAPEX of about Rs. 400 crores for the year, which will be capitalized incrementally over the quarters.
  • Depreciation expense increased due to commissioning of a new indoor manufacturing facility for the blended business.
  • Future CAPEX impact on depreciation will be reflected as and when assets are capitalized.
  • No large capital allocation planned for setting up manufacturing in the US due to pricing pressure and uncertain tariff impacts.

Track Alembic Pharma — get its next earnings analysis in your feed

How does Alembic Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAlembic Pharma
Rev 3Mar 3

How does Alembic Pharma rank in Pharmaceuticals & Biotechnology?

Compare Alembic Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY26) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →